Cargando…
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
Breast cancer is one the most common cause of cancer death in women worldwide. We report here the first phase II study investigating a virus genetically engineered for tumor-selective replication in patients with breast cancer. Ten patients were treated with a combination of low-dose oral cyclophosp...
Autores principales: | Cousin, Sophie, Toulmonde, Maud, Kind, Michèle, Guegan, Jean-Philippe, Bessede, Alban, Cantarel, Coralie, Bellera, Carine, Italiano, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724410/ https://www.ncbi.nlm.nih.gov/pubmed/36474303 http://dx.doi.org/10.1186/s40164-022-00338-2 |
Ejemplares similares
-
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022) -
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
por: Spalato-Ceruso, Mariella, et al.
Publicado: (2022) -
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
por: Breitbach, Caroline J, et al.
Publicado: (2015) -
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
por: Parato, Kelley A, et al.
Publicado: (2012) -
Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma
por: Kung, Che-Hsuan, et al.
Publicado: (2015)